Clinical Trial

Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 9, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2022-07-26; most recent amendment 2026-02-05.
Status change: Recruiting → Active, Not Recruiting 2026-02-05
Trial Details
NCT Number NCT05479812
Lead Sponsor Werewolf Therapeutics, Inc.
Collaborators: Merck Sharp & Dohme LLC
Conditions Metastatic Solid Tumor, Advanced Solid Tumor
Enrollment 150 participants
Start Date 2022-05-20
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-09